DekaBank Deutsche Girozentrale reduced its position in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 92.5% in the first quarter, HoldingsChannel reports. The firm owned 2,767 shares of the medical technology company’s stock after selling 33,900 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Hill-Rom were worth $269,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Hill-Rom by 3.5% during the 4th quarter. BlackRock Inc. now owns 6,350,899 shares of the medical technology company’s stock valued at $562,371,000 after purchasing an additional 215,770 shares in the last quarter. Vanguard Group Inc increased its stake in Hill-Rom by 0.6% during the 3rd quarter. Vanguard Group Inc now owns 5,916,827 shares of the medical technology company’s stock valued at $558,549,000 after purchasing an additional 34,369 shares in the last quarter. Oregon Public Employees Retirement Fund increased its stake in Hill-Rom by 8,755.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,308,056 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 2,281,991 shares in the last quarter. Bank of Montreal Can increased its stake in Hill-Rom by 5.0% during the 1st quarter. Bank of Montreal Can now owns 1,724,410 shares of the medical technology company’s stock valued at $182,547,000 after purchasing an additional 81,956 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Hill-Rom by 27.0% during the 4th quarter. Bank of New York Mellon Corp now owns 1,038,521 shares of the medical technology company’s stock valued at $91,961,000 after purchasing an additional 220,981 shares in the last quarter. Institutional investors and hedge funds own 81.31% of the company’s stock.
HRC has been the subject of a number of analyst reports. ValuEngine lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Needham & Company LLC restated a “buy” rating and set a $116.00 price objective on shares of Hill-Rom in a research note on Monday, March 11th. Zacks Investment Research upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $118.00 price objective for the company in a research note on Tuesday, April 16th. Finally, Barclays raised their price objective on shares of Hill-Rom from $103.00 to $108.00 and gave the company an “equal weight” rating in a research note on Monday, April 15th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $108.00.
Shares of HRC stock opened at $104.41 on Friday. Hill-Rom Holdings, Inc. has a 52 week low of $81.82 and a 52 week high of $108.68. The company has a market capitalization of $6.97 billion, a PE ratio of 21.98, a P/E/G ratio of 1.79 and a beta of 0.91. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.69 and a quick ratio of 1.27.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, April 26th. The medical technology company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.03. Hill-Rom had a net margin of 7.93% and a return on equity of 21.30%. The firm had revenue of $714.20 million during the quarter, compared to analyst estimates of $705.59 million. During the same period in the previous year, the business posted $1.05 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Equities research analysts anticipate that Hill-Rom Holdings, Inc. will post 5.05 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 21st will be paid a $0.21 dividend. The ex-dividend date is Thursday, June 20th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.80%. Hill-Rom’s dividend payout ratio is presently 17.68%.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2019/06/15/dekabank-deutsche-girozentrale-has-269000-holdings-in-hill-rom-holdings-inc-nysehrc.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: Understanding Market Liquidity
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.